We would love to hear your thoughts about our site and services, please take our survey here.
Sell when you don’t have to make a decision T/O price
Simple…..
GLA
So AS and the board build up a pipeline and are about to present the Holy Grail,
but they get prosecuted for sharing sensitive info with a small TG of investors.
Really …….
Massive Rainbow over UK
One hell of a lot of bed wetting last night.
Back to facts would she join if they were running out of money
Just a month ago nothing has changed
Christina Coughlin, M.D., Ph.D. as Head of Research and Development.
I am thrilled to join @avacta full time at such a pivotal time in the Company’s growth. Our #AVCT pipeline is truly game changing for patients with cancer and I am excited to get to work with this amazing team. #BringingHope #LetsDoThis
Christina Coughlin, M.D., Ph.D. as Head of Research and Development.
I am thrilled to join @avacta full time at such a pivotal time in the Company’s growth. Our #AVCT pipeline is truly game changing for patients with cancer and I am excited to get to work with this amazing team. #BringingHope #LetsDoThis
This could also be a route Avacta may be taking.
Drip feeding results and data to the FDA.
https://www.fda.gov/media/173641/download
Worth a read gives a good indication what the FDA look for in AA.
https://www.fda.gov/media/166431/download
Paddy 2 x clinics running trials:
Memorial Sloan Kettering Cancer Center
& Fred Hutchinson Cancer Center
Both have multiple locations ….
Have a good weekend everyone see you Monday……
Top gun Maverick , so researched thinks we need Phase 3 🤡🤡🤡
Thompi
Just spotted it, I just read the thread.
SP diving brings them all out.
“ Have you considered none of them is a strong possibility”
And your invested £500k
Yesterday:
Losing money
13 Feb 2024 19:52
Doggy to use your own self admission you are thick,
You can’t lose money until you sell. Really?
I bought £500K of Avacta shares accumulated in March 23 which I still hold and by my reckoning that’s £18k in lost interest that I will never get back
September:
RE: Hurst
7 Sep 2023 16:19
CJ62 I hope so too as I have a small holding in this biotech however I’m not taken in by all this blind hype and unhinged belief that this share will change everyone’s life. It could just as easily go the other way as most what appear to be promising biotechs usually do.
So £500k is a small holding go lick your D.ick and chase your tail
P.rick
Which one of these comes first this year…
1.Mega Licence deal
2.FDA approval
3.Full takeover
Sit tight GLA
RNS 13th Dec 2023 just 8 weeks ago.
The data confirm the pre|CISIONTM platform's ability to transform the safety profile of doxorubicin through tumour targeting
1. The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.
2. AVA6000 has significantly improved the safety and tolerability of doxorubicin.
3. AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity.
4. The next steps with AVA6000 involve optimising the patient population, dose and schedule in order to increase efficacy and tolerability of doxorubicin treatment via pre|CISIONTM targeting.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"Targeting potent therapies to the tumour, while limiting the systemic toxicity that often characterises these therapies, is one of the holy grails of cancer drug development. The data we released today show that the pre|CISION? modification is cleaved specifically by FAP, and not by other human enzymes, and this mechanism can be used to target the activation of a chemotherapy to the tumour microenvironment, significantly reducing the systemic exposure and improving the safety of the drug.
Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
"These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION? platform to avoid normal tissue effects while concentrating the toxin in the tumor microenvironment."
Well if you want sell your shares because a failed petty journalist who employs trolls on here and “X” to scaremonger and you believe his lies then Sell.
But read again paragraphs above from RNS in December.
Investing is all about research and then holding for gains.
GLA
Pushing the Avacta scientists
She knows what’s coming
GLA
It’s a Pfizer comercial…
https://m.youtube.com/watch?si=OicpajuxtuTygLPb&v=ZBanWqvE-hI&feature=youtu.be
Pfizer "Galileo, Copernicus, Isaac Newton" and Behind The Scenes Super Bowl LVIII(58)2024 Commercial
Christina tweeting again just 4 Hours ago.???
Some of us watch for the SuperBowl commercials … now ask again … what if female scientists were part of the conversation? Yeah. We’re part of it.
#LetsDoThis
Big Al
Just sign the bloody deal
Let LTH move on
RNS’s are very scarce at the moment, but we are guaranteed one in 6 weeks time.
Previous AACR RNS’s
AVA3996
RNS 27th March 2023 for AACR starting 16th April
AVA6000
RNS 29th March 2022 for
AACR starting 8th April
This years AACR April 5th expect RNS W/C 25th March.
This gives 2 weeks notice before AACR plus they need at least a month to QC the data so C7 must be very close to finishing.
A HO Let’s go